Regeneus Ltd's (ASX:RGS) Leo Lee speaks to Proactive's Andrew Scott while at the virtual ASX Small and Mid-Cap Conference 2020. They're an Australian biotech looking to improve the quality of life for patients suffering from pain. It develops regenerative medicine products that interrupt the inflammatory cascade that leads to pain.
Quick facts: Regeneus Ltd
Follow
ASX:RGS
Price: 0.076 AUD
Market Cap: $23.07 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
